



CANVECTOR

CanVECTOR

Annual Conference Program Brochure

October 25th, 2024

08:30 AM - 7:00 PM ET

Marriott Toronto Eaton Centre,
Toronto, ON, Canada

www.canvector.ca

*This program has been co-developed with integrity between
CanVECTOR and Thrombosis Canada*

ANNUAL CONFERENCE

Deepening Engagement in Research: From Patient Recruitment to Knowledge Translation

TABLE OF CONTENTS

Program Agenda



Scientific Planning Committee



Overall Meeting



Session Learning Objectives and Abstracts



Sponsor Acknowledgement



Click arrows to move directly to each section





ANNUAL CONFERENCE

Deepening Engagement in Research: From Patient Recruitment to Knowledge Translation

PROGRAM AGENDA (MORNING SESSIONS)

08:30 - 08:40	Welcome Remarks <i>Speakers: Tzu-Fei Wang & Teresa Cafaro</i>
08:40 - 09:00	CanVECTOR Leadership <i>Speakers: Susan Kahn & Grégoire Le Gal</i>
09:00 - 09:45	Keynote Presentation 1: Site Engagement & Patient Recruitment - What is Needed to Make Canada a World Leader in Clinical Trials - <i>Speaker: P.J. Devereaux</i>
09:45 - 10:00	BREAK & POSTER VIEWING
10:00 - 10:45	Keynote Presentation 2: Building Capacity for Research in Community Hospitals in Canada (RICH-Canada Program) - <i>Speaker: Jennifer Tsang</i>
10:45 - 11:30	Patients in Research: Some Good Practices <i>Speakers: Carol West, Dennis Christopher, Ming Wong, Suzanne Dubois</i>
11:30 - 12:00	3-Minute Project Competition <i>Speakers: Linnea Soon, Jared Treverton, Myanca Rodrigues, Ali Aftabjani</i>
12:00 - 13:00	LUNCH & POSTER PRESENTATIONS

Additional Details / Offerings

- **Registration:** Starts at 07:30
- **Breakfast / Lunch:** Served from 07:30-09:00 & 12:00-13:00
- **Photo headshots and group shots:** Available beginning at 11:00
- **Therapy dogs:** Relax with the furry friends from 11:00-14:00 (Simcoe Room)
- **Poster Presentations:** Authors will be available from 12:30-13:00



ANNUAL CONFERENCE

Deepening Engagement in Research: From Patient Recruitment to Knowledge Translation

PROGRAM AGENDA (AFTERNOON SESSIONS)

13:00 - 14:00	Drawing from Knowledge Translation Science to Mobilize Results from Clinical Trials for and with Patients, Providers and Health Systems - <i>Speaker: Justin Presseau</i>
14:00 - 14:45	Top 3 Rated Abstracts in the Scientific Abstract Competition <i>Speakers: Rex Huang, Sasha Sharma, Meriem Hammache</i>
14:45 - 15:00	BREAK & POSTER VIEWING
15:00 - 15:45	Breakout Session 1: Effective Grant Writing & Starting Clinical Trials <i>Speaker: Sandra Ofori</i>
15:00 - 15:45	Breakout Session 2: Navigating the World of Basic Science <i>Speakers: Edward Conway</i>
15:00 - 15:45	Breakout Session 3: Overcoming Patient Objections - Facilitating Understanding - <i>Speakers: Kailee Morrison & Maddy Hill</i>
15:45 - 16:00	BREAK & POSTER VIEWING
16:00 - 16:30	Fellowship Award Winner Presentations <i>Speakers: Amye Harrigan & Kwadwo Osei Bonsu</i>
16:30 - 16:45	Closing Remarks <i>Speakers: Tzu-Fei Wang & Teresa Cafaro</i>
16:45 - 19:00	Partner Recognition & Network Awards Reception <i>Moderators: Susan Kahn & Grégoire Le Gal</i>

Additional Details / Offerings

- **Featured Band during Partnership Reception:** [Down the Fire](#)



CANVECTOR 2024 ANNUAL CONFERENCE

SCIENTIFIC PLANNING COMMITTEE

Name	Position (CanVECTOR Group)	Credential
Tzu-Fei Wang	Hematologist – University of Ottawa (Investigator / Conference Co-chair)	MD, MPH
Teresa Cafaro	General Internist – McGill University (Investigator / Conference Co-chair)	MD, MSc, FRCPC
Suzanne Dubois	Patient Partner – Ontario (Patient Partner representative, CanVECTOR Scientific Steering Committee)	VTE lived experience
Amye Harrigan	Hematologist – Dalhousie University (Early Career Investigator / CanVECTOR Trainee Council Chair)	MD
Paul Kim	Associate Professor of Medicine - McMaster University (Investigator, Co-lead CanVECTOR Basic Science Platform)	PhD
Kailee Morrison	Research Coordinator – Niagara Health (Co-lead, CanVECTOR Research Coordinator Working Group)	BSc
Tania Pannu	General Internist – University of Calgary (2023 Conference Co-chair)	MD
Camille Simard	General Internist and Obstetric Medicine Physician – McGill University (Early Career Investigator)	MDCM MSc FRCPC
Ming Wong	Patient Partner - Ontario (CanVECTOR Patient Partner Council)	VTE lived Experience
Yan Xu	Hematologist – University of Ottawa (Early Career Investigator)	MD, MSc, FRCPC



OVERALL MEETING

WELCOME REMARKS (08:30)

Deepening Engagement in Research: From Patient Recruitment to Knowledge Translation

CONFERENCE CO-CHAIRS

- Dr. Tzu-Fei Wang MD, MPH
- Dr. Teresa Cafaro MD, MSc, FRCPC

PROGRAM LEARNING OBJECTIVES

After completing this program, participants will be equipped to:

- Explore the current landscape of clinical trials in Canada and employ practical methods to overcome common challenges in clinical trial planning and execution, including community hospitals engagement and enhancing patient participation
 - Apply strategies for knowledge translation planning and using creative strategies to mobilize research findings to impact change
 - Describe the current programming and research activities of the CanVECTOR network, including trainee research, and the potential impacts for venous thrombosis prevention, diagnosis, and treatment in the future
-

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION (08:40)

CanVECTOR Leadership Presentation

CONFERENCE CO-CHAIRS

- Susan Kahn MD MSc
- Grégoire Le Gal MD PhD

PROGRAM LEARNING OBJECTIVES

After completing this session, participants will be able to:

- Describe CanVECTOR Network accomplishments and activities over the last year
- Discuss CanVECTOR Network plans and projects for the coming year

PRESENTATION ABSTRACT

The co-Directors of the CanVECTOR Network will review recent research highlights and accomplishments of network members and the organization, focusing on potential impacts for the VTE research community.

They will outline strategic priorities for Phase 3 (2025-2030) identified by the Scientific Steering Committee and a survey of members, and will discuss opportunities for members to become involved and access network resources.

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION (09:00)

Keynote Presentation 1: Site Engagement & Patient Recruitment - What is Needed to Make Canada a World Leader in Clinical Trials

SPEAKER

- P.J. Devereaux, MD, PhD

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Apply knowledge gained to improve the conduct of trials in Canada
- Support the endeavours to improve the ecosystem for conducting trials in Canada
- Implement processes to accelerate the start up of trials in their centre.

PRESENTATION ABSTRACT

The presentation will review the landscape for conducting trials in Canada and the background to the accelerating clinical trials (ACT) Consortium. The presenter will discuss the initiatives undertaken by ACT to improve the ecosystem for conducting trials in Canada.

SESSION (10:00)

Keynote Presentation 2: Building Capacity for Research in Community Hospitals in Canada (RICH-Canada Program)

SPEAKER:

Jennifer Tsang, MD, PhD

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Discuss why it is important to include community hospitals in research
- Summarize the barriers and facilitators of research in community hospitals
- Describe the tangible support/resources that community hospitals need to conduct research.

PRESENTATION ABSTRACT

Most hospitals in Canada (>90%) are non-academic (community) hospitals and yet most health and clinical research are conducted in academic hospitals which make up <10% of all hospitals in Canada. In this talk, the presenter will discuss the strategies taken to increase research capacity in community hospitals in Canada.

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION (10:45)

Patient Partner Plenary Session: Patients in Research - Some Good Practices

SPEAKERS

- Dennis Christopher
- Suzanne Dubois
- Carol West
- Ming Wong

CanVECTOR Patient Partners; Lived Experience with VTE

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Identify obstacles to patients participating in research from stories of lived experiences
 - Discuss facilitators of patient participation in research
 - Discuss Issues surrounding fear related to blood clots
 - Recognize the quality of life and mental health concerns of patients
 - Identify and recommend resources for educating patients about VTE research and the underlying science
-

SESSION (11:30)

3-Minute Project Competition

SPEAKERS

- Linnea Soon, BHScH
- Jared Treverton, Honours BSc, PhD Candidate
- Myanca Rodrigues, MSc
- Ali Aftabjahani, PhD Student

PRESENTATION LEARNING OBJECTIVES

After completing this session, participants will be able to:

- Implement strategies to communicate engagingly with patients and community members
- Describe the clinical and scientific motivation for current research undertaken by CanVECTOR trainees
- Summarize potential implications of the research results for clinical practice

PRESENTATION ABSTRACT

Four CanVECTOR-supported trainees will describe their research projects and their potential impacts in a 3-minute presentation. The challenge is to present complex research in an engaging, accessible, and compelling way, using only one static slide.

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION (13:00)

Special Presentation: Drawing from Knowledge Translation Science to Mobilize Results from Clinical Trials for and with Patients, Providers and Health Systems

SPEAKER

Justin Presseau, MRes, PhD

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Describe approaches and strategies for supporting knowledge translation and practice change
- Draw from a toolkit of strategies for knowledge translation that could be included in future grant applications and/or knowledge mobilization activities
- Consider the role of knowledge translation from the bench to the bedside to practice and policy

PRESENTATION ABSTRACT

This presentation will provide an overview of strategies and approaches from implementation science and knowledge translation that can be leveraged across a range to optimize how the findings of clinical trials reach and support those who will use and benefit from trial findings.

SESSION: TOP RATED ABSTRACTS IN THE SCIENTIFIC ABSTRACT COMPETITION (14:00)

Abstract Presentation 1: Development of an ADAMTS13-based Therapy for Thrombosis

SPEAKER

Rex Huang, Graduate Student

PRESENTATION LEARNING OBJECTIVES

After completing this session, participants will be able to:

- Discuss the role of ADAMTS13 in Hemostasis/Thrombosis: ADAMTS13 regulates Von Willebrand Factor (VWF) to reduce thrombotic potential and its relevance in thrombosis treatment.
- Describe the development of a degradation-resistant ADAMTS13 Variant and how glycine-serine linker substitutions can enhance its resistance to proteolytic degradation.
- Discuss the functional activity of degradation-resistant ADAMTS13: Comparing the activity of the degradation-resistant ADAMTS13 variant with wild-type ADAMTS13 under both static and flow conditions using in vitro models.

PRESENTATION ABSTRACT

Thrombosis is the pathological formation of blood clots that occludes blood vessels and causes medical conditions like venous thromboembolism. Current therapies for thrombosis are limited by associated risks of significant bleeding. We aim to develop a novel thrombolytic therapy by exploring the antithrombotic properties of a degradation-resistant ADAMTS13 variant.



SESSION LEARNING OBJECTIVES, ABSTRACTS

Abstract Presentation 2: Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

SPEAKER

Sasha Sharma, BSc, MSc Student

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Discuss the limitations of diagnosing deep vein thrombosis in emergency departments within Canada
- Describe the methodology of the 2DAY algorithm

PRESENTATION ABSTRACT

Deep vein thrombosis diagnostic algorithms used in the emergency department are rarely followed by emergency physicians because of their complexity. We have developed the 2day algorithm to simplify the diagnosis of deep vein thrombosis for use in the emergency department. The objective of this study is to evaluate the safety and efficacy of the 2day algorithm. The 2day algorithm was found to be safe and efficient in ruling out dvt. Before the 2day algorithm can be implemented in daily clinical practice, a prospective validation study is required.

Abstract Presentation 3: Diagnosis of Suspected Pulmonary Embolism during Pregnancy - A Narrative Review

SPEAKER

Meriem Hammache, Medical Student

PRESENTATION LEARNING OBJECTIVES

After completing this session, participants will be able to:

- Describe the challenges associated with diagnosing pulmonary embolism during pregnancy
- Formulate a comprehensive approach in diagnosing pulmonary embolism during pregnancy that takes into consideration safety, diagnostic accuracy and individualized risk assessment

PRESENTATION ABSTRACT

Pulmonary embolism (PE) is a potentially life-threatening complication of pregnancy. It is one of the leading causes of pregnancy-related deaths in high-income countries, accounting for 3% of all maternal deaths. Additionally, physiological symptoms of pregnancy resemble early symptoms of PE, making its diagnosis challenging. Various diagnostic modalities and guidelines are available to guide the investigation of PE in pregnant women. We herein aimed to summarize the different available modalities for diagnosing PE, describing the accuracy of each method and its safety in use during pregnancy to assist healthcare professionals diagnosing PE during pregnancy.

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION: BREAKOUTS (15:00)

Clinical Breakout: Effective Grant Writing & Starting Clinical Trials

SPEAKER

Sandra Ofori, MBBS, MSc, PhD

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Apply knowledge of grant writing techniques to secure funding for clinical trials.
- Manage the administrative and regulatory aspects of initiating clinical trials efficiently.
- Implement strategies for the effective design and execution of clinical trials.

PRESENTATION ABSTRACT

Deep vein thrombosis diagnostic algorithms used in the emergency department are rarely followed by emergency physicians because of their complexity. We have developed the 2day algorithm to simplify the diagnosis of deep vein thrombosis for use in the emergency department. The objective of this study is to evaluate the safety and efficacy of the 2day algorithm. The 2day algorithm was found to be safe and efficient in ruling out dvt. Before the 2day algorithm can be implemented in daily clinical practice, a prospective validation study is required.

Basic Science Breakout: Navigating the World of Basic Science

SPEAKER

Edward Conway, MD, MBA, PhD

**This session is not accredited and is open only to basic science investigators and trainees*

Research Coordinators Breakout: Overcoming Patient Objections – Facilitating Understanding

SPEAKER

Kailee Morrison BSc, Maddy Hill BS

**This session is not accredited and is open only to research personnel and patient partners*

SESSION LEARNING OBJECTIVES, ABSTRACTS

SESSION: FELLOWSHIP AWARD WINNER PRESENTATIONS (16:00)

Fellowship Presentation 1: Cost-utility analysis of full-dose apixaban compared with reduced-dose apixaban for secondary thromboprophylaxis in patients with cancer-associated thrombosis

SPEAKER

Amye Harrigan, MD

PRESENTATION LEARNING OBJECTIVES

At the end of this presentation participants will be able to:

- Briefly review the current clinical data around the efficacy and safety of full-dose versus reduced-dose apixaban in the secondary prevention of venous thromboembolism (VTE) in patients with cancer.
- Provide an update on current economic analysis of full-dose apixaban versus reduced-dose apixaban for secondary VTE prevention in patients with cancer.

PRESENTATION ABSTRACT

Cancer-associated VTE management guidelines recommend continued therapeutic anticoagulation as long as active cancer persists. Emerging data now explore the safety and efficacy of full-dose versus reduced-dose apixaban for secondary VTE prevention in cancer patients. This research project aims to compare the health system costs and benefits of full-dose apixaban (5 mg orally twice daily) versus reduced-dose apixaban (2.5 mg orally twice daily) from the perspective of Canada's publicly funded healthcare system. This presentation provides an update on the current progress of the project.

Fellowship Presentation 2: Validation of Venous Thromboembolism Diagnosis and its epidemiology in Newfoundland and Labrador – A Retrospective Cohort Study

SPEAKER

Kwadwo Osei Bonsu, BPharm (HONS), PhD

PRESENTATION LEARNING OBJECTIVES

After completing this session, participants will be able to:

- Describe how to apply a comprehensive search strategy with an automated natural language technique to accurately identify positive VTE events from narrative diagnostic imaging reports
- Describe how to implement a comprehensive algorithm to accurately identify positive VTE events from various databases available in Canada for surveillance, program evaluation or research.
- Describe the contemporary population-based incidence of VTE and its associated outcomes in Newfoundland and Labrador

PRESENTATION ABSTRACT

Venous thromboembolism (VTE) has the potential for increased mortality, morbidity, and cost, prompting the need for effective methods for monitoring events. This study aimed to assess the accuracy of using natural language processing (NLP) techniques and outpatient anticoagulation prescription records for identifying DVT and PE from electronic medical records. By analyzing a randomly selected sample of narrative radiology reports from Newfoundland and Labrador patients suspected of DVT/PE, NLP models were implemented to identify positive DVT and PE with high accuracy, showcasing the potential of NLP in identifying VTE events from medical records.

SPONSOR ACKNOWLEDGEMENT

GOLD LEVEL



BRONZE LEVEL

